Nanjing Medlander Medical Stock Current Valuation
| 688273 Stock | 25.20 0.33 1.33% |
Valuation analysis of Nanjing Medlander Medical helps investors to measure Nanjing Medlander's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Nanjing Medlander's Free Cash Flow is projected to decrease significantly based on the last few years of reporting. The current year's Begin Period Cash Flow is expected to grow to about 1.2 B, whereas Cash is forecasted to decline to about 712.2 M. Fundamental drivers impacting Nanjing Medlander's valuation include:
Price Book 1.8991 | Enterprise Value 1.6 B | Enterprise Value Ebitda 13.4118 | Price Sales 6.6046 | Trailing PE 24.4272 |
Overvalued
Today
Please note that Nanjing Medlander's price fluctuation is not too volatile at this time. Calculation of the real value of Nanjing Medlander Medical is based on 3 months time horizon. Increasing Nanjing Medlander's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Nanjing Medlander is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Nanjing Stock. However, Nanjing Medlander's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 25.2 | Real 20.67 | Hype 25.23 | Naive 25.0 |
The real value of Nanjing Stock, also known as its intrinsic value, is the underlying worth of Nanjing Medlander Medical Company, which is reflected in its stock price. It is based on Nanjing Medlander's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Nanjing Medlander's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Nanjing Medlander Medical helps investors to forecast how Nanjing stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nanjing Medlander more accurately as focusing exclusively on Nanjing Medlander's fundamentals will not take into account other important factors: Nanjing Medlander Medical Company Current Valuation Analysis
Nanjing Medlander's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Nanjing Medlander Current Valuation | 1.58 B |
Most of Nanjing Medlander's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nanjing Medlander Medical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Nanjing Medlander Medical has a Current Valuation of 1.58 B. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The current valuation for all China stocks is notably lower than that of the firm.
Nanjing Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nanjing Medlander's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nanjing Medlander could also be used in its relative valuation, which is a method of valuing Nanjing Medlander by comparing valuation metrics of similar companies.Nanjing Medlander is currently under evaluation in current valuation category among its peers.
Nanjing Fundamentals
| Return On Equity | 0.0776 | ||||
| Return On Asset | 0.0386 | ||||
| Profit Margin | 0.27 % | ||||
| Operating Margin | 0.31 % | ||||
| Current Valuation | 1.58 B | ||||
| Shares Outstanding | 100 M | ||||
| Shares Owned By Insiders | 69.35 % | ||||
| Shares Owned By Institutions | 8.60 % | ||||
| Price To Book | 1.90 X | ||||
| Price To Sales | 6.60 X | ||||
| Revenue | 340.82 M | ||||
| Gross Profit | 376.75 M | ||||
| EBITDA | 105.63 M | ||||
| Net Income | 89.82 M | ||||
| Total Debt | 6.13 M | ||||
| Book Value Per Share | 13.38 X | ||||
| Cash Flow From Operations | 136.91 M | ||||
| Earnings Per Share | 1.03 X | ||||
| Number Of Employees | 481 | ||||
| Beta | -0.11 | ||||
| Market Capitalization | 2.52 B | ||||
| Total Asset | 1.53 B | ||||
| Retained Earnings | 244.7 M | ||||
| Working Capital | 1.04 B | ||||
| Annual Yield | 0.04 % | ||||
| Net Asset | 1.53 B | ||||
| Last Dividend Paid | 1.0 |
About Nanjing Medlander Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nanjing Medlander Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nanjing Medlander using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nanjing Medlander Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Nanjing Stock
Nanjing Medlander financial ratios help investors to determine whether Nanjing Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nanjing with respect to the benefits of owning Nanjing Medlander security.